or Try an Advanced Search...

    Technical Analysis for TERN - Terns Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    B 6.85 0.59% 0.04
    TERN closed up 0.59 percent on Monday, July 1, 2024, on 71 percent of normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Down
    Historical TERN trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Fell Below 20 DMA Bearish 0.59%
    Volume Surge Other 0.59%
    Wide Bands Range Expansion 0.59%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.66%
    Inside Day Range Contraction -3.66%
    Wide Bands Range Expansion -3.66%
    Fell Below 20 DMA Bearish 2.70%
    Wide Bands Range Expansion 2.70%
    Wide Bands Range Expansion -5.52%
    Older End-of-Day Signals for TERN ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 9 hours ago
    Down 3% about 9 hours ago
    Fell Below Previous Day's Low about 10 hours ago
    Down 2 % about 10 hours ago
    Down 1% about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    TERN Chart by TradingView
    Basic chart:

    Profile

    Terns Pharmaceuticals, Inc. Description

    Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase 2a clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase 1 clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Foster City, California.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Organ Systems Obesity Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Peptide Hormones Liver Glucagon Bile Acid Chronic Liver Diseases Anti Diabetic Drugs

    Is TERN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 21 Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
    Jun 4 Wall Street Analysts Believe Terns Pharmaceuticals (TERN) Could Rally 136.44%: Here's is How to Trade
    Jun 3 Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
    May 30 Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
    May 17 Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
    May 13 Terns Pharmaceuticals Inc (TERN) Q1 2024 Earnings: Misses Analyst Net Loss Projections
    May 13 Terns Pharmaceuticals GAAP EPS of -$0.30
    May 13 Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
    May 8 Terns Pharmaceuticals Announces Leadership Changes
    May 7 Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
    See more TERN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 8.68
    52 Week Low 3.26
    Average Volume 1,091,833
    200-Day Moving Average 5.91
    50-Day Moving Average 6.25
    20-Day Moving Average 7.14
    10-Day Moving Average 7.18
    Average True Range 0.59
    RSI (14) 49.49
    ADX 18.7
    +DI 23.26
    -DI 24.45
    Chandelier Exit (Long, 3 ATRs) 6.65
    Chandelier Exit (Short, 3 ATRs) 7.48
    Upper Bollinger Bands 8.26
    Lower Bollinger Band 6.02
    Percent B (%b) 0.37
    BandWidth 31.28
    MACD Line 0.18
    MACD Signal Line 0.30
    MACD Histogram -0.1245
    Fundamentals Value
    Market Cap 423.29 Million
    Num Shares 61.8 Million
    EPS -1.15
    Price-to-Earnings (P/E) Ratio -5.96
    Price-to-Sales 302.64
    Price-to-Book 1.50
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.65
    Resistance 3 (R3) 7.62 7.34 7.51
    Resistance 2 (R2) 7.34 7.13 7.35 7.47
    Resistance 1 (R1) 7.09 7.01 7.22 7.12 7.42
    Pivot Point 6.81 6.81 6.87 6.82 6.81
    Support 1 (S1) 6.56 6.60 6.69 6.59 6.28
    Support 2 (S2) 6.28 6.48 6.29 6.23
    Support 3 (S3) 6.03 6.28 6.19
    Support 4 (S4) 6.06